Trastuzumab deruxtecan

http://dbpedia.org/resource/Trastuzumab_deruxtecan an entity of type: Thing

トラスツズマブデルクステカン（Trastuzumab deruxtecan；T-DXd）は、ヒト化モノクローナル抗体であるトラスツズマブとトポイソメラーゼI阻害剤であるデルクステカン（エキサテカンの誘導体）を共有結合させた抗体薬物複合体である。乳癌、胃癌、胃食道腺癌の治療薬として認可されている。トラスツズマブは上皮成長因子受容体2（HER2/neu）に結合し、それに依存する癌のシグナル伝達を阻害する。さらにこの抗体は細胞内に取り込まれ、結合しているデルクステカンがDNAの複製を阻害することで細胞の増殖を妨げる。 2019年12月に米国で、2020年3月に日本で、2021年1月に欧州連合で、2021年10月にオーストラリアで医療用医薬品として承認された。日本では2020年3月に「化学療法歴のあるHER2陽性の手術不能又は再発乳癌（標準治療が困難な場合に限る）」を適応として、国内製造販売承認を取得。2020年5月25日に第一三共から「エンハーツ」として発売され、2021年度には、第一三共の売上高1兆円のうち、約800億円を売り上げる主力製品となった。 rdf:langString

Трастузумаб дерукстекан — лекарственный препарат для лечения рака молочной железы. Одобрен для применения: США (2019). rdf:langString

Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor (a derivative of exatecan). It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying rdf:langString

O trastuzumab deruxtecan, vendido sob a marca Enhertu, é um conjugado anticorpo-droga que consiste no anticorpo monoclonal humanizado trastuzumab (Herceptin) covalentemente ligado ao inibidor da topoisomerase I deruxtecan (um derivado do exatecano ). É licenciado para o tratamento de câncer de mama ou adenocarcinoma gástrico ou gastroesofágico. O trastuzumabe se liga e bloqueia a sinalização através do receptor 2 do fator de crescimento epidérmico (HER2/neu) em cânceres que dependem dele para o crescimento. Além disso, uma vez ligado aos receptores HER2, o anticorpo é internalizado pela célula, levando consigo o deruxtecano ligado, onde interfere na capacidade da célula de fazer alterações estruturais no DNA e replicar seu DNA durante a divisão celular, levando a danos no DNA quando o célu rdf:langString

rdfs:label

rdf:langString トラスツズマブデルクステカン

rdf:langString Trastuzumab deruxtecan

rdf:langString Трастузумаб дерукстекан

dbpedia-owl:wikiPageID

xsd:integer 62630349

dbpedia-owl:wikiPageRevisionID

xsd:integer 1102613869

dbpprop:atcSuffix

rdf:langString FD04

dbpprop:atcPrefix

rdf:langString L01

dbpprop:casNumber

xsd:integer 1826843

dbpprop:chembl

xsd:integer 4297844

dbpprop:drugbank

rdf:langString DB14962

dbpprop:kegg

rdf:langString D11529

dbpprop:legalStatus

rdf:langString Rx-only

dbpprop:legalUk

rdf:langString POM

dbpprop:legalUs

rdf:langString Rx-only

dbpprop:source

rdf:langString zu

dbpprop:synonyms

rdf:langString DS-8201a, fam-trastuzumab deruxtecan-nxki

dbpprop:tradename

rdf:langString Enhertu

dbpprop:type

rdf:langString mab

dbpprop:unii

xsd:integer 5384

dbpprop:width

xsd:integer 360

dbpedia-owl:abstract

rdf:langString Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor (a derivative of exatecan). It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell. It was approved for medical use in the United States in December 2019, in Japan in March 2020, in the European Union in January 2021, and in Australia in October 2021. Trastuzumab deruxtecan is the first approved therapy by the US Food and Drug Administration (FDA) targeted to people with the HER2-low breast cancer subtype subset of HER2-negative breast cancer.

rdf:langString トラスツズマブデルクステカン（Trastuzumab deruxtecan；T-DXd）は、ヒト化モノクローナル抗体であるトラスツズマブとトポイソメラーゼI阻害剤であるデルクステカン（エキサテカンの誘導体）を共有結合させた抗体薬物複合体である。乳癌、胃癌、胃食道腺癌の治療薬として認可されている。トラスツズマブは上皮成長因子受容体2（HER2/neu）に結合し、それに依存する癌のシグナル伝達を阻害する。さらにこの抗体は細胞内に取り込まれ、結合しているデルクステカンがDNAの複製を阻害することで細胞の増殖を妨げる。 2019年12月に米国で、2020年3月に日本で、2021年1月に欧州連合で、2021年10月にオーストラリアで医療用医薬品として承認された。日本では2020年3月に「化学療法歴のあるHER2陽性の手術不能又は再発乳癌（標準治療が困難な場合に限る）」を適応として、国内製造販売承認を取得。2020年5月25日に第一三共から「エンハーツ」として発売され、2021年度には、第一三共の売上高1兆円のうち、約800億円を売り上げる主力製品となった。

rdf:langString O trastuzumab deruxtecan, vendido sob a marca Enhertu, é um conjugado anticorpo-droga que consiste no anticorpo monoclonal humanizado trastuzumab (Herceptin) covalentemente ligado ao inibidor da topoisomerase I deruxtecan (um derivado do exatecano ). É licenciado para o tratamento de câncer de mama ou adenocarcinoma gástrico ou gastroesofágico. O trastuzumabe se liga e bloqueia a sinalização através do receptor 2 do fator de crescimento epidérmico (HER2/neu) em cânceres que dependem dele para o crescimento. Além disso, uma vez ligado aos receptores HER2, o anticorpo é internalizado pela célula, levando consigo o deruxtecano ligado, onde interfere na capacidade da célula de fazer alterações estruturais no DNA e replicar seu DNA durante a divisão celular, levando a danos no DNA quando o célula tenta se replicar, destruindo a célula. Foi aprovado para uso médico nos Estados Unidos em dezembro de 2019, no Japão em março de 2020, na União Europeia em janeiro de 2021, e na Austrália em outubro de 2021.

rdf:langString Трастузумаб дерукстекан — лекарственный препарат для лечения рака молочной железы. Одобрен для применения: США (2019).

dbpprop:chemicalFormula

rdf:langString C6460H9972N1724O2014S44.8

dbpprop:dailymedid

rdf:langString Trastuzumab_deruxtecan

dbpprop:legalAu

rdf:langString S4

dbpprop:legalCa

rdf:langString Rx-only

dbpprop:legalEu

rdf:langString Rx-only

dbpprop:licenceUs